论文部分内容阅读
“靶向给药系统”是一种“导弹式”的超微粒药物载体,将抗癌药物包封于大多用高分子物质构成的载体中,把这些运载抗癌药物的超微粒载体通过各种给药途径(大多数是静脉注射或口服)给药后,能将药物导向靶区(癌变部位或直接作用于癌细胞),使抗癌药物的剂量减少,疗效提高,毒副作用降低。这种抗癌药物新剂型研究中的设想,在我们设计的多相脂质体的大量基础理论研究工作与临床观察中,初步得到了证实。所以化疗药物的“靶向给药系统”已成为治疗恶性肿瘤中较有希望的新途径。“靶向给药系统”包括:前体药物的一部分、静脉乳、脂质体与多相脂质体、毫微型胶囊、微球剂、含磁性微球剂、β—环糊精分子胶襄以及琼脂聚糖小球等。靶向的方式主要是通过淋巴定向、由巨噬细胞对超微粒载体的吞噬作用和融合作用、对癌细胞的亲合力、酶类对前体药物的作用以及磁性定位等。
The Targeted Drug Delivery System is a “missile-style” ultrafine drug carrier that encapsulates anticancer drugs in a carrier that is mostly made of high molecular material, and these ultra-fine particle carriers that carry anticancer drugs are passed through various The route of administration (most of which is intravenous or oral) can direct the drug to the target area (the cancerous site or act directly on the cancer cells) to reduce the dose of the anticancer drug, improve the curative effect and reduce the side effects. The idea of this new anticancer drug formulation research was tentatively confirmed in a large number of basic theoretical research and clinical observations of the multiphase liposomes we designed. Therefore, the “targeted drug delivery system” of chemotherapy drugs has become a promising new way to treat malignant tumors. Targeted drug delivery systems include a portion of prodrugs, venous milk, liposomes and multiphase liposomes, nanocapsules, microspheres, magnetic microspheres, beta-cyclodextrin molecules And agarose beads and so on. Targeting mainly through the lymphatic orientation, macrophage phagocytosis and fusion of the ultrafine particle carrier, affinity for cancer cells, the role of enzymes on the prodrugs and magnetic localization.